
|Videos|June 2, 2014
Are Expensive New Hepatitis C Drugs Worth the High Cost?
Author(s)Davy James, Associate Editor
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
Advertisement
Stephen Vogt, PharmD, Chief Executive Officer and President of BioPlus Specialty Pharmacy, discusses the ongoing debate surrounding the high price of Hepatitis C treatments versus the efficacy of the drug.
This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Panel Unanimously Backs Moderna’s Breakthrough mRNA Flu Vaccine Amid Political Turbulence
2
Elevating Precision Medicine in Breast Cancer Care
3
Sonrotoclax Plus Zanubrutinib Achieves Undetectable MRD Rates Above 90% in Frontline CLL/SLL
4
Are Non-Opioid Therapies Finally Challenging Opioids in Acute Pain Management?
5





















































































































